Crispr Therapeutics AG (CRSP) Major Shareholder Sells $5,058,560.00 in Stock

Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 256,000 shares of the stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $19.76, for a total transaction of $5,058,560.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total transaction of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total transaction of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total transaction of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $520,200.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total transaction of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.44, for a total transaction of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total transaction of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total transaction of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total transaction of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total transaction of $304,762.50.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.01 during mid-day trading on Thursday, hitting $18.53. 197,500 shares of the stock traded hands, compared to its average volume of 142,711. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. During the same quarter last year, the business earned ($2.77) EPS. The firm’s revenue for the quarter was up 54.2% on a year-over-year basis. equities research analysts expect that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in shares of Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the period. Capital Investment Advisory Services LLC acquired a new stake in shares of Crispr Therapeutics in the third quarter valued at about $193,000. Ark Investment Management LLC acquired a new stake in shares of Crispr Therapeutics in the second quarter valued at about $206,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Crispr Therapeutics in the third quarter valued at about $235,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Crispr Therapeutics in the second quarter valued at about $273,000. Hedge funds and other institutional investors own 24.55% of the company’s stock.

Several brokerages have issued reports on CRSP. BidaskClub downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. SunTrust Banks reissued a “hold” rating and set a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Barclays restated a “buy” rating and issued a $29.00 target price on shares of Crispr Therapeutics in a research note on Friday, September 8th. Finally, Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $22.38.

WARNING: “Crispr Therapeutics AG (CRSP) Major Shareholder Sells $5,058,560.00 in Stock” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-sells-5058560-00-in-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply